Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia

Journal of Clinical Oncology

Volumn 26, Issue 15, 2008, Pages 2519-2525

  Andritsos, Leslie A ^a   Johnson, Amy J ^a   Lozanski, Gerard ^a   Blum, William ^a   Kefauver, Cheryl ^a   Awan, Farrukh ^a   Smith, Lisa L ^a   Lapalombella, Rosa ^a   May, Sarah E ^a   Raymond, Chelsey A ^a   Wang, Da Sheng ^a   Knight, Robert D ^a   Ruppert, Amy S ^a   Lehman, Amy ^a   Jarjoura, David ^a   Chen, Ching Shih ^a   Byrd, John C ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD86 ANTIGEN; LENALIDOMIDE; PREDNISONE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; THALIDOMIDE;

ABDOMINAL PAIN; ADULT; AIRWAY OBSTRUCTION; APOPTOSIS; ARTICLE; ARTIFICIAL VENTILATION; B LYMPHOCYTE; BACKACHE; CASE REPORT; CELL ACTIVATION; CHRONIC LYMPHATIC LEUKEMIA; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPNEA; FEVER; HOSPITALIZATION; HUMAN; HUMAN TISSUE; HYPERPHOSPHATEMIA; HYPERURICEMIA; HYPOXIA; KIDNEY FAILURE; LACTATE DEHYDROGENASE BLOOD LEVEL; LETHARGY; LEUKAPHERESIS; LEUKOCYTE COUNT; LYMPH NODE ENLARGEMENT; LYMPHADENOPATHY; MENTAL HEALTH; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; RELAPSE; RESPIRATORY FAILURE; SEPSIS; SIDE EFFECT; TONSIL DISEASE; TONSIL HYPERTROPHY; TREATMENT OUTCOME; TUMOR CELL DESTRUCTION; TUMOR FLARE; TUMOR LYSIS SYNDROME; UPREGULATION; WEAKNESS; B CELL LEUKEMIA; CELL CULTURE; DOSE RESPONSE; DRUG EFFECT; FLOW CYTOMETRY; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; ANTINEOPLASTIC AGENTS; APOPTOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL RATE; THALIDOMIDE; TUMOR CELLS, CULTURED;

EID: 45149115902     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.9709     Document Type: Article

References (30)

1. Marriott JB, Clarke IA, Dredge K, et al: Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol 130:75-84, 2002
2. Mangiameli DP, Blansfield JA, Kachala S, et al: Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma. J Transl Med 5:38-46, 2007
3. Tai YT, Li XF, Catley L, et al: Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: Clinical implications. Cancer Res 65:11712-11720, 2005
4. Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, et al: Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 11:5984-5992, 2005
5. LeBlanc R, Hideshima T, Catley LP, et al: Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 103:1787-1790, 2004
6. Pellagatti A, Jadersten M, Forsblom AM, et al: Lenalidomide inhibits the malignant clone and upregulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci U S A 104:11406-11411, 2007
7. List A, Kurtin S, Roe DJ, et al: Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352:549-557, 2005
8. List A, Dewald G, Bennett J, et al: Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355:1456-1465, 2006
9. Richardson PG, Schlossman RL, Weller E, et al: Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100:3063-3067, 2002
10. Richardson PG, Blood E, Mitsiades CS, et al: A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108:3458-3464, 2006
11. Rajkumar SV, Hayman SR, Lacy MQ, et al: Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106:4050-4053, 2005
12. Chanan-Khan A, Miller KC, Musial L, et al: Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study. J Clin Oncol 24:5343-5349, 2006
13. Ferrajoli A OBS, Faderl SH, Wierda WG, et al: Lenalidomide induces complete and partial responses in patients with relapsed and treatment-refractory chronic lymphocytic leukemia. Blood 108:305, 2006 (abstr 305)
14. Byrd JC, Lin TS, Dalton JT, et al: Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109:399-404, 2007
15. Cheson BD, Bennett JM, Grever M, et al: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996
16. Lossos IS, Czerwinski DK, Wechser MA, et al: Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies. Leukemia 17:789-795, 2003
17. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408, 2001
18. O'Brien SM, Cunningham CC, Golenkov AK, et al: Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol 23:7697-7702, 2005
19. O'Brien S, Moore JO, Boyd TE, et al: Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 25:1114-1120, 2007
20. Bedikian AY, Millward M, Pehamberger H, et al: Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The Oblimersen Melanoma Study Group. J Clin Oncol 24:4738-4745, 2006
21. Badros AZ, Goloubeva O, Rapoport AP, et al: Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. J Clin Oncol 23:4089-4099, 2005
22. Marcucci G, Stock W, Dai G, et al: Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: Pharmacokinetics, pharmacodynamics, and clinical activity. J Clin Oncol 23:3404-3411, 2005
23. Jahrsdorfer B, Hartmann G, Racila E, et al: CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol 69:81-88, 2001
24. Decker T, Schneller F, Kronschnabl M, et al: Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: Costimulation with IL-2 results in a highly immunogenic phenotype. Exp Hematol 28:558-568, 2000
25. Decker T, Schneller F, Sparwasser T, et al: Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 95:999-1006, 2000
26. Castro JE, Prada CE, Aguillon RA, et al: Thymidine-phosphorothioate oligonucleotides induce activation and apoptosis of CLL cells independently of CpG motifs or BCL-2 gene interference. Leukemia 20:680-688, 2006
27. Moutouh-de Parseval LA, Weiss L, DeLap RJ, et al: Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia. J Clin Oncol 25:5047, 2007
28. Padmanabhan S, Wallace PK, Miller KC, et al: First clinical evidence of in vivo natural killer (NK) cell modulation in chronic lymphocytic leukemia (CLL) patients (pts) treated with lenalidomide (L). Blood 108:2109, 2006 (abstr 2109)
29. Johnson AJ, Lucas DM, Muthusamy N, et al: Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood 108:1334-1338, 2006
30. Bichi R, Shinton SA, Martin ES, et al: Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci U S A 99:6955-6960, 2002